The 2nd domestic DPP-4 inhibitor attracted attention with high expectation of global commercialization

The DPP-4(dipepitdyl peptidase-4) diabetes new drug developed by Dong-A ST for the second time as a domestic company, Evogliptin, is expected to become a role model of the global commercialization.

This is because there is now a high chance that the product will become the future devoted product as expanded to China, Latin American countries, such as Brazil and Mexico, and Russia.

According t...